Health News

For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.

Read more

Filed under: Pharmacy News
Tags: brain, Pharmacy, Tumor

Related posts

• Wake Forest Baptist participates in novel brain tumor vaccine clinical trial (0)
  A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate. Read more [tags] Pharmacy News [/tags]
  
  
• Valproic acid may increase survival for brain tumor patients (0)
  New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures. Read more [tags] Pharmacy News [/tags]
  
  
• Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers (0)
  A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology. Read [...]
  
  
• UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009 (0)
  Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New [...]
  
  
• UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009 (0)
  Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New [...]